We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+11.58%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$904M
AUM Growth
+$113M
Cap. Flow
+$79M
Cap. Flow %
8.74%
Top 10 Hldgs %
30.09%
Holding
103
New
13
Increased
46
Reduced
23
Closed
11

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$14.7M
2
ABBV icon
AbbVie
ABBV
+$12.4M
3
UNH icon
UnitedHealth
UNH
+$9.71M
4
AXSM icon
Axsome Therapeutics
AXSM
+$9.24M
5
PRCT icon
Procept Biorobotics
PRCT
+$9.13M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$13.9M
2
THC icon
Tenet Healthcare
THC
+$13.8M
3
HCA icon
HCA Healthcare
HCA
+$11.4M
4
VRNA
Verona Pharma
VRNA
+$10.1M
5
GILD icon
Gilead Sciences
GILD
+$10M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACLX
51
DELISTED
Arcellx
ACLX
$5.36M 0.59%
65,250
-2,000
-3% -$144K
APLS
52
DELISTED
Apellis Pharmaceuticals
APLS
$5.26M 0.58%
232,250
+139,000
+149% +$3.24M
PEN icon
53
Penumbra
PEN
$12.9B
$5.19M 0.57%
20,500
-1,000
-5% -$252K
GPCR icon
54
Structure Therapeutics
GPCR
$3.74B
$5.04M 0.56%
180,100
+45,000
+33% +$896K
MRUS
55
DELISTED
Merus
MRUS
$5.04M 0.56%
53,500
-62,500
-54% -$4.07M
BRKR icon
56
Bruker
BRKR
$8.57B
$5.01M 0.55%
154,315
+31,000
+25% +$1.1M
NTRA icon
57
Natera
NTRA
$45.8B
$4.99M 0.55%
31,000
-26,500
-46% -$4.19M
PRVA icon
58
Privia Health
PRVA
$2.82B
$4.84M 0.54%
194,189
+103,000
+113% +$2.22M
NUVL
59
DELISTED
Nuvalent
NUVL
$4.54M 0.5%
52,500
– –
INSP icon
60
Inspire Medical Systems
INSP
$1.75B
$4.53M 0.5%
61,000
+30,500
+100% +$3.09M
KURA icon
61
Kura Oncology
KURA
$879M
$4.34M 0.48%
490,000
+240,000
+96% +$1.71M
MIRM icon
62
Mirum Pharmaceuticals
MIRM
$6.1B
$4.12M 0.46%
56,255
-9,500
-14% -$604K
RDNT icon
63
RadNet
RDNT
$5.95B
$3.81M 0.42%
50,000
+4,000
+9% +$260K
VERA icon
64
Vera Therapeutics
VERA
$2.24B
$3.78M 0.42%
+130,000
New +$3.01M
IQV icon
65
IQVIA
IQV
$39.9B
$3.7M 0.41%
19,500
+6,500
+50% +$1.18M
VCEL icon
66
Vericel Corp
VCEL
$2.29B
$3.68M 0.41%
117,000
+59,000
+102% +$2.12M
RARE icon
67
Ultragenyx Pharmaceutical
RARE
$2.66B
$3.59M 0.4%
119,400
+26,300
+28% +$789K
BNTX icon
68
BioNTech
BNTX
$23.2B
$3.54M 0.39%
35,870
– –
RYTM icon
69
Rhythm Pharmaceuticals
RYTM
$7.94B
$3.53M 0.39%
+35,000
New +$3.25M
TGTX icon
70
TG Therapeutics
TGTX
$7.69B
$3.36M 0.37%
93,000
-22,000
-19% -$725K
UTHR icon
71
United Therapeutics
UTHR
$22.6B
$3.35M 0.37%
+8,000
New +$2.69M
XENE icon
72
Xenon Pharmaceuticals
XENE
$6.2B
$3.25M 0.36%
81,000
+46,000
+131% +$1.62M
NRIX icon
73
Nurix Therapeutics
NRIX
$2.69B
$3.21M 0.36%
347,500
+162,500
+88% +$1.69M
GH icon
74
Guardant Health
GH
$22.4B
$3.12M 0.35%
+50,000
New +$2.72M
ALKS icon
75
Alkermes
ALKS
$8.25B
$2.82M 0.31%
94,000
+55,000
+141% +$1.55M
1 2
3
4 5

Similar funds

ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return
AF
Ally Financial Detroit, Michigan $804M AUM 0.18% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2025 Portfolio in Review

As of Q3 2025, Rhenman & Partners Asset Management held 103 positions worth $904M, up 14% from $791M the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Rhenman & Partners Asset Management deployed $79M of net new capital in Q3 2025, opening 13 new positions and adding to 46 existing holdings. Its largest new stake was Madrigal Pharmaceuticals: 18,250 shares worth $8.37M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Tenet Healthcare, an estimated $13.8M trimmed.

  • Rhenman & Partners Asset Management's largest Q3 2025 buy was Madrigal Pharmaceuticals: 18,250 shares worth $8.37M.
  • Rhenman & Partners Asset Management added most to Boston Scientific in Q3 2025, an estimated $14.7M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2025 reduction was Tenet Healthcare, cutting an estimated $13.8M.
  • Rhenman & Partners Asset Management fully exited DexCom in Q3 2025, selling an estimated $13.9M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 30% of its $904M portfolio in Q3 2025.
  • Rhenman & Partners Asset Management opened 13 new positions and closed 11 in Q3 2025.
  • Rhenman & Partners Asset Management's portfolio value rose 14% quarter-over-quarter to $904M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2025, filed 13 Nov 2025.